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A B S T R A C T
We describe, for the ﬁrst time, the design, production and evaluation of large microneedle patches. Such
systems, based on 16 individual microneedle arrays (needle height 600 mm), were prepared from
aqueous blends of 15% w/w Gantrez1 S97 and 7.5% w/w poly(ethyleneglycol) 10,000 Da. Ester-based
crosslinking was conﬁrmed by FTIR and mechanical strength was good. Insertion depths in a validated
skin model were approximately 500 mm. Ten human volunteers successfully self-inserted the
microneedles of these larger patches in their skin, following appropriate instruction, as conﬁrmed by
transepidermal water loss measurements. The mean insertion depth ranged between 300 and 450 mm
over the area of the large patches. That this was not signiﬁcantly different to a single unit MN patch self-
applied by the same volunteers is encouraging. Microneedle patch sizes much larger than the 1–2 cm2
will be required if this technology is to be successfully translated to clinic for delivery of drug substances.
The work described here suggests that use of such larger patches by patients can be successful,
potentially opening up the possibility for a signiﬁcant expansion of the size of the market for transdermal
drug delivery.
© 2017 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Microneedle (MN) arrays are minimally-invasive devices that
are used to penetrate the skin’s outermost layer, the stratum
corneum (SC), which is the principal barrier to topically-applied
drugs (Donnelly et al., 2012b; Larrañeta et al., 2016c; Prausnitz
2004). MN arrays are currently of great interest to the pharma-
ceutical industry, due to the number of advantages they possess
over traditional methods of drug delivery, such as oral and
parenteral administration. Some of the beneﬁts include the ability
to painlessly administer the active pharmaceutical ingredient,
bypass of hepatic ﬁrst pass metabolism and extension of the range
of types of drug that can be delivered intradermally and
transdermally (Tuan-Mahmood et al., 2013).
A wide variety of substances have been successfully delivered
transdermally and intradermally using MN arrays (Donnelly et al.,
2012a; Larrañeta et al., 2016a; Prausnitz 2004; Tuan-Mahmood
et al., 2013). However, the predominant focus in the ﬁeld has been
on vaccines (Henry et al., 1998; McGrath et al., 2011). This is hardly
surprising, given the potential for stable, dry state formulation, the
avoidance of needle-stick injuries common with hypodermic
syringes, dose-sparing through direct targeting of viable skin’s
abundance of professional antigen-presenting cells and the self-
disabling nature of dissolving MN. Indeed, MN vaccines have the
potential to revolutionise vaccination, especially in the developing
world. In studies where delivery of therapeutic drug substances
using has been exempliﬁed, the focus has tended to be on
illustration of the capability of MN in delivering a substance with
particular physicochemical characteristics and little mention is
typically made of the actual amount delivered or its relevance to
therapeutic human doses.
Vaccines tend to be quite potent and so delivery of even
microgram quantities of antigen, antigen/adjuvant combination,
virus-like particle or even DNA is often sufﬁcient to elicit an
immune response, especially when targeted to the viable
epidermis and/or dermis. This means that small, postage stamp-
sized MN patches that can be inserted into skin by fairly gentle
thumb pressure are sufﬁcient to achieve successful vaccination.
Our own work has focused strongly on delivery of therapeutically-
relevant doses of drugs using MN patches (Donnelly et al., 2012a,
2014b; Kearney et al., 2016). We have measured plasma levels in
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animal models and extrapolated to estimate suitable patch sizes
for achievement of therapeutic plasma levels in humans. Since
most commonly-used small molecule drugs tend to require oral
doses in the range of tens to hundreds of milligrams daily, the
patch sizes we have estimated have ranged from 10 cm2–30 cm2.
Such patch sizes are well within the range of marketed
transdermal patches. Indeed, Novartis market Nicotinell1 (nico-
tine) patches of 30 cm2 (Novartis, 2017), while Janssen market
Duragesic1 CII (fentanyl) patches of 32 and 42 cm2 (Janssen, 2017),
for example. MN patches of such sizes could clearly not be
effectively inserted into skin using a single thumb. Since it is our
opinion that patients will be more accepting of a large MN patch
that can be applied by hand rather than an applicator device, we
sought here, for the ﬁrst time, to examine the ability of human
volunteers to successfully use large MN patches.
2. Material and methods
2.1. Materials
Gantrez1 S-97 (Mw = 1.2  106Da), a copolymer obtained from
the free acid of methyl vinyl ether and maleic anhydride polymers,
was provided by Ashland (Tadworth, Surrey, UK). Poly(ethylene
glycol) (PEG, molecular weight 10,000 Da) was purchased from
Sigma-Aldrich (Steinheim, Germany). Paraﬁlm M1, a ﬂexible
thermoplastic sheet (127 mm thickness) made of oleﬁn-type
material and used as a skin simulant for insertion studies, was
obtained from BRAND GMBH (Wertheim, Germany). In order to
build the MN patch, an adhesive dressing, TegadermTM (3M, St
Paul, USA), and a pressure-responsive ﬁlm, Pressurex-micro
Green1 (Sensor Products Inc., Madison, USA) were used.
2.2. Fabrication of hydrogel-forming MN arrays
MN arrays were prepared using aqueous blends containing 15%
w/w Gantrez1 S-97 and 7.5% w/w PEG 10,000. The formulation
(0.5 g/cm2) was carefully syringed onto silicone micromoulds
(14 14 needles on a 0.5 cm2 area, 600 mm needle height). The
needle cavities were ﬁlled after applying positive pressure (3–
4 bar) to the formulation for 15 min. MN arrays were left to dry for
48 h at room temperature and were then crosslinked by esteriﬁca-
tion through heating at 80 C for 24 h (Donnelly et al., 2012a,
2014b; Larrañeta et al., 2015; Lutton et al., 2015b). The MN arrays
were stored under ambient until assembled into large patches.
2.3. MN array characterization
MN were inspected using a Leica EZ4 D digital microscope
(Leica, Wetzlar, Germany) and a Keyence VHX-700F digital
microscope (Keyence, Osaka, Japan).
Attenuated total reﬂectance (ATR) Fourier transform infrared
(FTIR) spectroscopy was used to evaluate the crosslinking of MN
arrays. The IR spectra were recorded at room temperature using a
FTIR Accutrac FT/IR-4100 Series (Jasco, Essex, UK) equipped with
MIRacleTM software from 4000 to 600 cm1, with a resolution of
4.0 cm1. The obtained spectra were the result of averaging 64
scans.
Axial compression forces (i.e. forces applied perpendicular to
the needle base) were applied to MN arrays in order to evaluate
needle strength. A known load was applied to the MN arrays in
axial compression mode of a TA.XT-Plus Texture Analyser (Stable
Micro Systems, Surrey, UK). MN arrays were attached to the
moving test probe of the Texture Analyser using double-sided
adhesive tape. The MN arrays were then pressed against a ﬂat block
of aluminium at a rate 0.5 mm s1 until a maximum force of 30 N
per array was applied. The change in needle height was evaluated
using the Leica EZ4 D digital microscope.
Paraﬁlm1 M (PF) ﬁlm was used as a skin simulant for MN
insertion studies, as described previously (Larrañeta et al., 2014).
MN arrays were inserted into a sheet assembled from 8 layers of
Paraﬁlm1 using the Texture Analyser, with the probe lowered onto
the artiﬁcial membrane at a speed of 0.5 mm s1, with an exerted
force of 30 N per array, held for 30 s. The MN arrays were removed
from the polymeric sheet after insertion, the PF sheet unfolded and
the number of holes in each layer was evaluated using the Leica
EZ4 D digital microscope. In order to ease the detection of the
created holes in the PF layers, the sample was placed between two
polarizer ﬁlters. The thickness of each PF layer was determined
previously to be 126  7 mm (Larrañeta et al., 2014) and this
knowledge was used to calculate the percentage of MN success-
fully inserted as a function of depth.
2.4. Assembly of large patches from individual microneedle arrays
Large MN patches were assembled by using the adhesive
properties of TegadermTM ﬁlms (10 cm  12 cm) to attach 16
individual MN arrays (Fig. 1). To the reverse, non-adhesive side of
the assembled patches, the pressure-responsive Pressurex-micro
Green1 indicator sensor ﬁlms were attached using double-sided
adhesive tapes. Pressurex-micro Green1 changes colour from
white to red when pressures >20 N cm2 are applied. Notably,
colour changes are only seen on areas of the ﬁlm where the
pressure exceeds the cut-off. Below this, the microparticles from
the red donor layer are not transferred to the white receiver layer.
We have previously shown that pressures of approximately
10 N cm2 are sufﬁcient to successfully insert hydrogel-forming
MN into human skin in vivo. Accordingly, Pressurex-micro Green1
serves as a useful patient feedback tool, conﬁrming MN insertion.
For larger MN patches, where correct insertion of each individual
array will be required for consistent dosing, addition of such site-
speciﬁc feedback will be vital.
2.5. Volunteer recruitment
Ten healthy volunteers (6 men and 4 women), aged between 20
and 30 years old, with no pre-existing skin conditions were
recruited to the study by means of an email circular. Volunteers
were asked not to apply cosmetic formulations to their upper arm
or forearm 24 h prior to the study and to avoid hot showers/baths
or exercise immediately before the study. Volunteers were
provided with a patient information leaﬂet and a volunteer
information sheet detailing the aims and objectives of the study,
their contribution and, in particular, the risks associated and the
conﬁdentiality of the results obtained upon recruitment. The
School of Pharmacy Research Ethics Committee, Queen’s Univer-
sity Belfast, approved this study. All volunteers were asked to
conﬁrm their fully-informed consent by signing an appropriate
form prior to participating in the study (See Supporting Informa-
tion). All data was anonymised and stored on ﬁrewalled servers in
password-protected ﬁles and was scheduled for destruction 2
years after completion of the study. Only the researchers directly
involved in the study had access to the data.
2.6. Patient information leaﬂet and counselling
The patient information leaﬂet (PIL) used in this study (See
Supporting Information) was prepared with particular emphasis
on existing PILs for transdermal patches’ (e.g. BuTrans1). Reference
was made to PILs for other products (e.g. metred-dose inhalers)
that require a more descriptive protocol and the inclusion of
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Figures to ensure volunteers would feel conﬁdent enough in
applying the patches correctly.
The views of in-house microneedle researchers and patient-
facing scientists involved in pharmacy practice research were
considered when designing the PIL, to ensure appropriate format
and content. The PIL was also then checked for best practice against
the criteria laid out in “Quality Criteria for PILs” published by the
UK’s Medicines & Healthcare Products Regulatory Agency (MHRA,
2016) to ensure it was of an appropriate standard. PILs are normally
supplied with medicinal products and devices when the patient is
expected to use them by themselves. Medicinal packs are required
to include a PIL if the label does not contain all the necessary
information. Upon dispensing medicinal products, such as our MN
patches to a patient, it is normal practice for the pharmacist to
provide counselling on how the product is to be used successfully.
A strategy for counselling every volunteer was developed,
following discussion. This consisted primarily of details concerning
MN fabrication and technology, how to hold and apply the patches
(force required was described as “pressing an elevator button
ﬁrmly”), what the pressure-indicating sensor ﬁlm was used for,
what exactly was going to be recorded using an optical coherence
tomography instrument (VivoSightTM Topical Multi-Beam OCT
Handheld Probe, Michelson Diagnostics Ltd, Kent, UK) and, ﬁnally,
how to remove and dispose of the patch (Table 1).
2.7. Volunteer application protocol
The study was conducted at a controlled room temperature of
20 C and a relative humidity of 45  5%. The volunteers were
acclimatised to the room for 10 min before starting the experiment.
During their wait, subjects were presented with the PIL and
volunteer information sheet and allowed to read about the
application technique of the patches alongside counselling from
the researcher(s).
Table 1
Researcher counselling points on microneedle patch application protocol to human volunteers.
Point
1
“Using an alcohol wipe, rub your upper arm gently, to ensure the area of application is clean to provide clear images using optical coherence tomography.”
Point
2
“Feel that the microneedle patch is at the bottom of the packaging. The pressure-responsive ﬁlm should be facing upwards. Gently pull open the TegadermTM
patch ensuring you do not press on the microneedle arrays when doing so, as this may damage the microneedles”
Point
3
“Place the microneedle patch with the microneedles facing into your upper arm and ensure the TegadermTM adhesive border adheres to your skin. Gently pull the
protective layer off the receiving layer of your pressure-responsive ﬁlm and fold over the red layer. Press on the area of your patch ﬁrmly and evenly. Hold this
pressure for around 45 s”
Point
4
“Stop applying pressure and peel off the red ﬁlm of your pressure-responsive ﬁlm to ensure you have applied even pressure across the whole patch. The
researcher will then sequentially take scans of ﬁve different areas of the patch.”
Point
5
“Gently peel off the TegadermTM ﬁlm, pulling the adhesive ﬁlm away from you to minimise removal pain. Place the used patch in the original packing it came in
and dispose of”
Point
6
“Any skin redness is only temporary and is not a cause for concern”
Fig. 1. TegadermTM patch comprised of 16 individual MN arrays (A). MN patch numbered at the positions where the Optical Coherence Tomography (OCT) scans were taken
(B). OCT image of a single MN penetrating a volunteer’s skin (C).
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Each application used a new MN patch. The four corners of
where the patch was to be applied were marked on the volunteer’s
upper arm. Before the volunteers applied the patches, baseline
transepidermal water loss (TEWL) values were recorded at the
edge of where the patch was to be applied and at the centre by
carefully resting the TEWL probe (VapoMeter1, Delﬁn Technolo-
gies Ltd, Kuopio, Finland) on the application site, with the probe
head vertical and perpendicular to the skin, to give an indication of
skin barrier function. TEWL measures the outward diffusion of
water through the skin and, as such, provides information on the
barrier status (Vicente-Pérez et al., 2016). Measurement of TEWL is
often used as an alternative to invasive measures of skin barrier
integrity obtained by local excision or biopsy. Indeed, the
technique has been frequently used in our previous MN-based
studies, due to its patient-friendly non-invasive nature and
capability for rapid and accurate data generation. TEWL measure-
ments were taken, with values recorded for a period of 10–15 s and
expressed in g m2 h1.
Each volunteer was then presented with the large MN patch
within its package (moisture-impermeable, heat-sealable non-
woven poly(ester) ﬁlm, Transparent Film Products Ltd, New-
townards, UK) and asked to apply it to their upper arm, peel back
the protective ﬁlm on the receiving layer of the pressure-
responsive ﬁlm and apply pressure for 45s, following the steps
detailed in the PIL. The pressure-responsive ﬁlm was then peeled
back, to ensure that the red colour was evenly distributed, hence
indicating that sufﬁcient and even pressure was applied by the
volunteer to the patch.
The patch was numbered from one to ﬁve, at each corner and
the middle, in order to be able to take ﬁve different scans of the MN
penetrating the skin (Fig. 1B), using optical coherence tomography
(OCT) (Fig. 1C). Once the subject had removed the patch from their
arm, the TEWL was again measured at the edge and centre of
where the patch had been applied.
The transepidermal water loss of the volunteer’s forearm was
then measured and an individual MN array was applied by the
volunteers to their forearm. Using their thumb, pressure was
applied to the MN for 45 s. The pressure-responsive ﬁlm was
removed and again OCT was used to take a scan of the MN
penetrating the volunteer’s skin. One more TEWL measurement
was made to determine the difference in outward diffusion of
water after subsequent removal of the MN.
Volunteers were revisited after 15 min, 1 h and 24 h to check for
any adverse skin sensations or reactions and a digital picture
(Nikon CoolpixTM, Nikon, Tokyo, Japan) of their upper arm was
taken at each time interval under controlled and consistent
lighting conditions.
2.8. MN insertion parameters
Since TEWL does not give an indication of MN penetration
depth, or the diameter of the created micropores, OCT technology
was used to scan images of the MN penetrating the volunteers’
skin. OCT was used, as described previously (Donnelly et al., 2012a;
Donnelly et al., 2014a), to study microneedle penetration depth
and micropore diameter and to determine whether all 16 arrays of
a large patch had successfully penetrated the stratum corneum.
Data was presented as means (S.D.) of 5 replicate measure-
ments of MN penetration depth and the diameter of the
corresponding micropore for each of 5 microneedle arrays per
patch. The MN penetration depth/micropore diameters were
selected at random from the 196 penetrating microneedles
comprising each array (each of the ﬁve scans taken). Quantiﬁcation
was performed using the imaging software ImageJ1 (National
Institute of Health, Maryland, USA). The scale of the image ﬁles
obtained was 1.0 pixel = 4.2 mm, thus allowing accurate
measurements of the depth of MN penetration and the diameter
of micropores created.
OCT was also used to scan images of the MN penetrating the
skin of the volunteers’ forearms, after having applied the single MN
array. Data was presented as means (S.D.) of 10 replicate
measurements of MN penetration depth and the diameter of the
corresponding micropores of the single MN array. The MN
penetration depth/micropore diameters were selected at random
from the 196 penetrating MN in the array. Again, quantiﬁcation
was performed using ImageJ1.
2.9. Volunteer application force measurement
After having applied both the large MN patch and the individual
MN array, the volunteers’ application/insertion force was approxi-
mated over a period of 45 s, using the Texture Analyser in tension
mode, as described previously (Larrañeta et al., 2014). Three
different readings were taken of the forces applied by each
volunteer and the minimum, maximum and mean force (Larrañeta
et al., 2014).
2.10. Questionnaire
A structured questionnaire, consisting of 7 ﬁxed questions was
developed. Questionnaires were designed after consulting with
MN researchers and registered, patient-facing, pharmacists. With
ethical committee approval and fully-informed consent, the paper-
based written questionnaires were provided to the volunteers once
the insertion/application study was complete. The questionnaire
was used to evaluate the volunteers’ thoughts and feedback on the
self-application of larger MN patches compared to individual MN
and also their overall opinion on the potential of this technology
and design (scale strongly positive to strongly negative 1–10).
Quantitative data obtained was analysed using Microsoft Excel1
(Microsoft Corporation, Redmond, USA).
2.11. Statistical analysis
Statistical analysis was performed using the Wilcoxon Signed
Rank test and Kruskal-Wallis test, as appropriate. In all cases,
p < 0.05 denoted signiﬁcance.
3. Results
3.1. Microneedle characterisation
Before starting insertion studies, the manufactured MN arrays
were tested. Optical microscopy was used to ascertain the
geometry and morphology of the arrays. Fig. 2A shows a 3D
reconstruction of some needle tips from one of the arrays, showing
the pyramidal geometry.
A crucial step in manufacture of hydrogel-forming MN is the
chemical crosslinking of the polymers that form the arrays.
Infrared spectroscopy is the most convenient way to evaluate the
crosslinking reaction. Fig. 2B shows the IR spectra of MN arrays
before and after the crosslinking reaction. It is noticeable that the
crosslinked arrays present a noticeable new carbonyl peak at
around 1800 cm1. This shows that the esteriﬁcation reaction
between Gantrez1 S97 and PEG took place.
MN should have sufﬁcient mechanical strength to be inserted
successfully in the skin without failure during insertion. The
compression testing (Fig. 2C–E) shows that there is a needle height
reduction after compressing them against an aluminium block
(Fig. 2C and D). This reduction ranges between a 5 and a 15% of the
original height (Fig. 2E). It should be noted, though, that the
needles were compressed against a metal block and this situation
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is far from simulating the insertion of MN into the skin. This test
was simply used to compare different batches of MN arrays and
conﬁrm consistency of manufacture, which it did. Finally, the
insertion of the arrays was evaluated by using a validated skin
simulant model (Larrañeta et al., 2014). The insertion proﬁle
(Fig. 2F) shows that the needles can theoretically reach insertion
depths of 500 mm.
3.2. Microneedle self-application
Fig. 3A shows the post-removal increase in the TEWL values
after volunteer self-application of a single MN patch and a patch
comprised of multiple MN arrays. When patches comprised of
multiple arrays were used, TEWL was measured in the centre of the
application site and at one edge. The results showed that there is no
signiﬁcant difference between the application of single MN arrays
and multi-array patches in terms of skin barrier disruption
(p = 0.405). For large patches, the data shows that there is no
inﬂuence from the measuring site (p = 0.083), in that the TEWL
values obtained after MN removal at the centre of the application
site are equivalent to those obtained from one edge of the
application site.
The skin appearance of two representative volunteers can be
seen in Fig. 3B. In both examples, it is noticeable that erythema can
Fig. 3. TEWL values before and after self-application of single MN arrays and patches comprised of multiple arrays (A). After the application of the multi-array patches TEWL
was measured in the centre and at one edge of the region to which the larger patch was applied. Skin appearance following removal of larger patches in two representative
volunteers (B).
Fig. 2. 3D reconstruction of needle tips from a MN array (A). FTIR spectra of MN arrays before and after crosslinking (B). Microscopy images of MN arrays before (C) and after
(D) compression study. Needle height reduction after compression (E). Insertion proﬁle in Paraﬁlm1 for MN (F). (Means  SD, n = 3).
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be found immediately after MN removal. After 15 min, the
erythema begins to dissipate. After 1 h, erythema was not
noticeable for the volunteers.
In order to ascertain the insertion of the arrays into the patient’s
skin, OCT was used. Fig. 4A shows the mean insertion depths of a
single MN array and a multi-array patch in the volunteer’s skin. The
mean insertion depths ranged between 300 and 450 mm. As can be
observed in Fig. 4A, there are no notable differences (p > 0.05 in
each case) in insertion depths for MN of the larger patch and
individual patch inserted by the same volunteer. Fig. 4B shows the
diameter of the created micropores after MN insertion in the
volunteers’ skin. The pore diameter ranged from 300 to 450 mm.
Fig. 4. Insertion depth (A) and diameter of the created micropores (B) after the self-application of single and multi-array patches by 10 volunteers.
Fig. 5. Scanned images of the pressure-indicating sensor ﬁlms used as a low-cost insertion feedback mechanism during self-application of large MN patches by human
volunteers.
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Again, no statistically-signiﬁcant differences were observed for any
of the volunteers (p > 0.05 in each case) between the single and
larger patches.
Fig. 5 shows the pressure responsive ﬁlms after application of
large MN patches. It can be seen that, in all cases, the ﬁlms turned
red, indicating that sufﬁcient pressure was applied over the entire
region of the patch to allow successful skin insertion of MN.
The insertion depth data presented in Fig. 4 represents mean
insertion depths over the ﬁve speciﬁed regions of the multi-array
patches. The insertion depth distribution over the entire patch
surfaces can be seen in Fig. 6. It is interesting to note that insertion
depths range between 200 and 400 mm over the surface of the
patches. While insertion depth clearly varied between regions and
between volunteers, it is important to realise that, in all measured
cases, MN penetrated the stratum corneum and were inserted to a
minimum depth of 200 mm.
Fig. 7A shows the maximum, minimum and average force
applied by the volunteers when following the same instructions as
for MN application and measured using the Texture Analyser. The
distribution of forces was wide and some volunteers, such as
Volunteer 1 and Volunteer 2, applied noticeably higher forces that
the others. The lowest forces were applied by Volunteer 8 and
Volunteer 9. Nevertheless, if one compares the applied forces with
the mean insertion depths (Fig. 7B), it can be seen that insertion
Fig. 6. Insertion distribution of self-applied MN multi-array over the patch surface for all the different volunteers.
Fig. 7. Maximum, minimum and mean forces applied by the volunteers when following the same instructions as for MN application/insertion (A). MN insertion as a function
of the measured mean force applied by the volunteers (B). It is important to note than the insertion force and the insertion depth measurements were obtained in separate
experiments.
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depth is not necessarily dependent upon the forces applied by
these volunteers. It may well be that the minimum insertion force
required for these arrays is considerably lower than the forces
applied by the volunteers.
As can be seen from Table 2, the volunteers were generally
positive about MN technology and most found application/
insertion of both the larger MN patches and the individual MN
array to be pain-free. The volunteers did ﬁnd the individual array
easier to use and some expressed concerns about inter-patient
variability in application. However, 8 out of the 10 volunteers were
conﬁdent that they had applied the large MN patches correctly
themselves.
4. Discussion
Despite criticism about the speed of development and clinical
translation, for a relatively new ﬁeld, MN technology has actually
made considerable progress since the ﬁrst research work was
published in 1998 (Henry et al., 1998). During this time, a vast
number of types of MN arrays, including solid metal and silicon,
dissolving polymeric, hollow and hydrogel-forming MN have all
been investigated as delivery systems (Larrañeta et al., 2016c;
Prausnitz 2004; Tuan-Mahmood et al., 2013).
The focus of the ﬁeld to date has largely been on vaccine
delivery, meaning only small MN patches would be required for
successful use in humans. While the earliest work was rightly
centred on the fundamental science of delivery and understanding
of the resulting physiological effects, recent years have seen
enhanced emphasis on translation to patient beneﬁt and
commercial return, with several notable companies making
progress towards commercialisation. Indeed, a number of studies
examining patient usability (Birchall et al., 2011; Donnelly et al.,
2014a; Vicente-Pérez et al., 2016), scaled-up manufacture and
quality control testing (Larrañeta et al., 2015, 2016b; Lutton et al.,
2015b), sterile production (McCrudden et al., 2015a) and regula-
tory considerations (Lutton et al., 2015a) have now been published.
MN with applications in improving skin appearance are now
available commercially, though it is notable that these are not
approved drug products (McCrudden et al., 2015b).
Our own translationally-focussed work has suggested that
dissolving MN arrays and hydrogel-forming MN arrays can both
potentially be used for the delivery of high drug doses sufﬁcient to
Table 2
Views and opinions obtained from 10 human volunteers using a structured questionnaire.
Questions asked about large microneedle patch application Number of volunteers that stated answer
Q1. Do you believe this method of microneedle application has potential for drug delivery?
YES 10
Q2. Did you ﬁnd the PIL helpful and easy to understand?
YES 9
NO 1
Q3. What limitations or problems do you think may be encountered with the general patient population using large microneedle patches?
1. Inter-patient variability in applying pressure or skin thickness 10
2. Not conﬁdent the drug had entered the body uniformly 3
3. Potential for misuse and abuse 0
4. Possible high cost of microneedles compared to hypodermic injection 3
5. Pain associated with administration could result in low patient compliance 0
Q4. What advantages do you think larger microneedle patches have compared to individual arrays?
1. Less painful than hypodermic injection 9
2. Possibility of self-administration 10
3. Less bleeding 8
4. Less tissue damage 7
5. Less needle stick injuries 9
6. Reduced fear of injection 10
7. Reduced frequency of administration compared to individual arrays 7
Q5. Please rate how painful the application of (1) the individual microneedle array and (2) the larger microneedle patch was using the provided visual analogue scale,
where 0 = no pain and 10 = very painful
0–3 9
4–7 1
8–10 0
0–3 9
4–7 1
8–10 0
Q6. Please rate how easy the application of (1) the individual microneedle array and (2) the larger microneedle patch was using the provided visual analogue scale, where
0 = very easy and 10 = very difﬁcult
0–3 9
4–7 1
8–10 0
0–3 7
4–7 2
8–10 1
Q7. Indicate on the provided visual analogue scale how conﬁdent you are that you applied the large microneedle patches correctly, where 0 = not conﬁdent at all and
10 = very conﬁdent
0–3 0
4–7 2
8–10 8
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elicit therapeutic effects in humans, providing patch size is
appropriate (Donnelly et al., 2014b; McCrudden et al., 2014). As
described previously, hydrogel-forming MN arrays seem to be the
most suitable candidate for the delivery of higher doses of
therapeutic molecules. They are not limited by the amount of drug
loaded inside the needle tips, as the drug is incorporated in an
attached patch-type reservoir (Donnelly et al., 2012a). By
optimising the formulation, this type of system is capable of
delivering high doses of low potency drugs without depositing
measurable amounts of polymer in skin (Donnelly et al., 2014b).
MN patch size has never before been a consideration, due to the
potency of most vaccines. However, in order to deliver therapeuti-
cally-relevant doses of most drugs, much larger MN patches will be
required, even for hydrogel-forming MN. Ideally, such patches
would not exceed the sizes of already marketed transdermal
patches, so as to be acceptable to patients. They should also be able
to be reliably and reproducibly applied by all patients, following
suitable instruction or counselling. Successful translation of such a
technology would clearly create a signiﬁcant opportunity for
industry in terms of expanding the size of the transdermal market,
which has now been in stagnation for several years, with few new
drug candidates in the pipeline (Watkinson et al., 2016).
Accordingly, our focus in the present study was to ascertain, for
the ﬁrst time, how successfully larger MN patches could be applied
by human volunteers.
Here, we have shown that multi-array large MN patches can be
successfully prepared by assembling together single arrays using
an adhesive patch. The needles themselves exhibited good
mechanical properties, as they did not break during direct
compression and showed deeper insertion proﬁles than those
reported by us previously (Lutton et al., 2015b), possibly due to the
move from conical to pyramidal needle designs.
The use of larger MN patches inevitably changes the way in MN
are applied/inserted. To date, MN have been inserted into skin
manually, or by using an applicator device (Singh et al., 2011;
Vicente-Pérez et al., 2016). Such approaches work relatively well
for small patches, as the applied force is easily focused over a small
area. For a larger patch, several ﬁngers, or the palm of the hand will
be required to ensure even insertion of the needles distributed over
the entire area of the patch. A rigid applicator device would most
likely not be suitable for patches greater in area than around 5 cm2,
due to the curvature of the human body. This also means that the
baseplate upon which the MN of a single-unit large MN patch are
formed, or the adhesive backing to which numerous individual
smaller MN arrays are attached to make up the larger MN patch,
must exhibit a degree of ﬂexibility to avoid cracking. For manual
application of larger patches, a means of patient feedback will be
essential. It is conceivable that a patient will not apply sufﬁcient
force to the entire area of a large patch and so inconsistent needle
penetration will result, leading to inconsistent drug dosing.
Here, we showed that the large MN patches, comprised of 16
individual arrays assembled on a ﬂexible adhesive backing were self-
inserted by human volunteers as effectively as single MN arrays. The
pressure-responsive indicator ﬁlm changed colour in each case,
providing instant feedback on successful insertion. Despite variation
in applied pressures and differences in depths of insertion at
different sites across the patch areas, the stratum corneum barrier
was always overcome, with minimum insertion depths of 200 mm
observed in all cases. Volunteer feedback was positive, providing
encouragement for further development of this approach.
5. Conclusion
This work has shown that large MN patches can be produced in
a simple manner and effectively self-inserted by human volunteers
provided with appropriate instruction and that a low-cost
pressure-responsive ﬁlm can provide accurate real-time conﬁr-
mation of successful insertion. Our work continues to centre on
exempliﬁcation of delivery of therapeutically-relevant doses of
drug substances using our hydrogel-forming MN technology, with
scaled-up manufacture to GMP standards and clinical translation a
strong current focus.
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